Overview
Cryo-Cell fiscal Q3 revenue decreased 3% yr/yr to $7.83 mln
The cord blood bank firm's net income for fiscal Q3 fell to $749,000 from $1.05 mln yr/yr
Outlook
Company did not provide specific guidance for future quarters or the full year in the press release
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$7.83 mln
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Cryo-Cell International Inc is $8.50, about 41.2% above its May 16 closing price of $5.00
Press Release: ID:nBw6LZvy4a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)